Gamma-aminobutyric acid type A receptor alpha-1 beta-2 gamma-2 subunit benzodiazepine site (GABA_A receptor α1β2γ2 BZD site)

The Gamma-aminobutyric acid type A (GABA_A) receptor alpha-1 beta-2 gamma-2 subunit benzodiazepine site is a high-affinity allosteric binding site located at the extracellular interface of the alpha-1 and gamma-2 subunits (Ernst et al., 2003). This specific heteromeric configuration, alpha-1 beta-2 gamma-2, represents the most abundant GABA_A receptor subtype in the mammalian central nervous system, accounting for approximately 60% of all GABA_A receptors (Pirker et al., 2000). As a ligand-gated chloride channel, the receptor mediates fast inhibitory neurotransmission; binding of positive allosteric modulators (PAMs) like benzodiazepines to this site increases the frequency of channel opening in response to GABA, leading to neuronal hyperpolarization (Sigel and Lüscher, 2011). This site is the primary target for a wide range of clinically important drugs used to treat anxiety, insomnia, and epilepsy, with the alpha-1 subunit specifically mediating the sedative and hypnotic effects (Rudolph and Moehler, 2006). However, chronic activation of this site is associated with significant therapeutic challenges, including the development of tolerance, physical dependence, and a potentially severe withdrawal syndrome (Hansen and Atkinson, 2020). Additionally, the site can be targeted by neutral antagonists like flumazenil to reverse benzodiazepine overdose or by negative allosteric modulators (NAMs) which have pro-convulsant properties (Mody and Pearce, 2004). The alpha-1 subunit's role in sedation makes it a key focus for the development of selective hypnotic agents like zolpidem, which show preference for this isoform over others (Whiting, 2006).

Other names

Benzodiazepine receptorBZD siteBZ1 receptorGABA(A) receptor alpha1beta2gamma2Omega-1 receptor

Positive allosteric modulation (PAM) of the GABA_A receptor, which increases the frequency of chloride channel opening in response to GABA; competitive antagonism of the benzodiazepine binding site; and negative allosteric modulation (NAM) which decreases GABA-induced currents.